TM4SF5 and hepatocellular carcinoma: It is thus worthwhile to explore antibody-drug conjugates or combinations of ICIs to target HCC, involving sorafenib, anti-VEGF(R) reagents, and/or anti-TM4SF5 reagents like TSIs and antibodies.22,43